Brief: Tharimmune Acquires Global License & Partners With Intract Pharma To Develop Oral Formulation Of Infliximab
16/09/2024 12:33
Sept 16 (Reuters) - Tharimmune Inc THAR.O :
* THARIMMUNE ACQUIRES GLOBAL LICENSE & PARTNERS WITH INTRACT
PHARMA TO DEVELOP ORAL FORMULATION OF INFLIXIMAB
Source text for Eikon: ID:
Further company coverage: THAR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing